Live Analyst Rating Changes 54325 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Derek Archila
WF

Derek Archila

Wells Fargo
Wall Street Analyst
★★★☆☆
#2068
on 13Foresight · ranked by our own returns
48%
Success Rate
+3.3%
Average Return
73 of 152 calls profitable · +22.9% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 48% of Derek Archila's ratings turned a profit when each position was held for 1 year — averaging +3.3% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

159 Buy 44 Hold 2 Sell
Derek's Stock Coverage 64 ratings · 2026-11-10
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
ANNX
Annexon Biosciences
 Oct 30, 2026 BUY Strong Buy
+274.8% avg upside
14 analysts
$27.00
566.63% Upside
 +3.7% ·
BBIO
BridgeBio Pharma
 Oct 30, 2026 BUY Strong Buy
+26.0% avg upside
36 analysts
$102.00
36.01% Upside
 +0.4% ·
XFOR
X4 Pharmaceuticals
 Oct 30, 2026 BUY Strong Buy
+612.9% avg upside
16 analysts
$11.00
228.28% Upside
 -8.4% ·
INCY
Incyte
 Oct 29, 2026 HOLD Strong Buy
-5.9% avg upside
49 analysts
$127.00
5.48% Upside
 +2.4% ·
ALNY
Alnylam Pharma
 Oct 29, 2026 HOLD Strong Buy
+76.3% avg upside
53 analysts
$220.00
33.34% Upside
 -10.0% ·
KYMR
Kymera Therapeutics
 Oct 29, 2026 BUY Strong Buy
-9.6% avg upside
39 analysts
$151.00
19.16% Upside
 +13.3% ·
XNCR
Xencor
 Oct 27, 2026 BUY Strong Buy
+31.8% avg upside
29 analysts
$44.00
47.58% Upside
 +12.5% ·
ARGX
Argenx Se
 Oct 22, 2026 BUY Strong Buy
-8.2% avg upside
48 analysts
$1336.00
49.59% Upside
 +9.9% ·
IRON
Disc Medicine
 Oct 20, 2026 BUY Strong Buy
+23.4% avg upside
21 analysts
$124.00
53.36% Upside
 -1.3% ·
PFE
Pfizer
 Oct 16, 2026 HOLD Buy
+9.1% avg upside
46 analysts
$28.00
8.23% Downside
 +0.8% ·
IMVT
Immunovant
 Oct 16, 2026 BUY Strong Buy
+38.4% avg upside
25 analysts
$45.00
54.18% Upside
 +28.5% ·
ONC
BeOne Medicines
 Oct 16, 2026 BUY Strong Buy
-1.2% avg upside
29 analysts
$400.00
8.11% Upside
 +10.3% ·
PYXS
Pyxis Oncology
 Oct 16, 2026 BUY Strong Buy
+349.6% avg upside
15 analysts
$19.00
949.82% Upside
 +5.1% ·
VOR
Vor Biopharma
 Oct 16, 2026 BUY Strong Buy
+117.6% avg upside
19 analysts
$30.00
52.46% Upside
 +14.1% ·
ALXO
ALX Oncology Holdings
 Oct 16, 2026 BUY Strong Buy
+1370.8% avg upside
11 analysts
$5.00
309.85% Upside
 +21.2% ·
ORIC
Oric Pharmaceuticals
 Oct 16, 2026 BUY Strong Buy
+160.3% avg upside
21 analysts
$25.00
170.48% Upside
 -22.4% ·
CLDX
Celldex
 Oct 15, 2026 BUY Strong Buy
+42.9% avg upside
28 analysts
$72.00
139.28% Upside
 +3.2% ·
NTLA
Intellia Therapeutics
 Oct 15, 2026 HOLD Buy
+187.2% avg upside
39 analysts
$15.00
20.27% Upside
 +0.1% ·
VRDN
Viridian Therapeutics
 Oct 14, 2026 BUY Strong Buy
+42.6% avg upside
32 analysts
$31.00
25.71% Upside
 +55.0% ·
TRAX
First Tracks Biotherapeutics Inc
 Oct 13, 2026 BUY Strong Buy
+64.6% avg upside
11 analysts
$70.00
55.23% Upside
 +51.2% ·
QTTB
Q32 Bio
 Oct 01, 2026 BUY Strong Buy
+523.8% avg upside
28 analysts
$59.00
562.17% Upside
 +12.1% ·
KYTX
Kyverna Therapeutics, Inc.
 Sep 25, 2026 BUY Strong Buy
+382.1% avg upside
8 analysts
$33.00
482.08% Upside
 -28.3% ·
ALMS
Alumis Inc.
 Sep 09, 2026 BUY Strong Buy
+361.9% avg upside
11 analysts
$25.00
271.51% Upside
 -38.5% ·
SEPN
Septerna, Inc.
 Sep 09, 2026 BUY Strong Buy
+17.7% avg upside
12 analysts
$50.00
13.54% Upside
 +33.6% ·
NRIX
Nurix Therapeutics
 Sep 01, 2026 HOLD Strong Buy
+22.5% avg upside
28 analysts
$25.00
6.65% Downside
 -41.2% ·
ASND
Ascendis Pharma
 Aug 14, 2026 BUY Strong Buy
+12.3% avg upside
29 analysts
$326.00
29.68% Upside
 +4.6% ·
CCCC
C4 Therapeutics
 Aug 12, 2026 BUY Strong Buy
+405.9% avg upside
21 analysts
$10.00
196.65% Upside
 -19.2% ·
ATYR
aTyr Pharma
 Aug 10, 2026 HOLD Buy
+69.8% avg upside
17 analysts
$1.00
79.68% Downside
 · ·
ARVN
Arvinas Holding Company
 Aug 05, 2026 HOLD Buy
+257.9% avg upside
28 analysts
$11.00
39.85% Upside
 -19.5% ·
RYTM
Rhythm Pharmaceuticals
 Jul 16, 2026 BUY Strong Buy
+39.2% avg upside
23 analysts
$155.00
67.36% Upside
 -1.0% ·
GLUE
Monte Rosa Therapeutics
 Jun 24, 2026 BUY Strong Buy
+108.5% avg upside
16 analysts
$29.00
169.54% Upside
 -49.3% ·
EXEL
Exelixis
 Feb 11, 2026 HOLD Buy
-34.0% avg upside
34 analysts
$35.00
49.59% Downside
 +6.8% ·
ANAB
AnaptysBio
 Dec 16, 2025 BUY Strong Buy
+48.7% avg upside
26 analysts
$81.00
67.73% Upside
 +59.8% ·
CQP
Cheniere Energy Partners
 Dec 16, 2025 SELL Sell
-21.6% avg upside
25 analysts
$56.00
15.87% Downside
 -17.2% ·
PTCT
PTC Therapeutics
 Oct 17, 2025 BUY Buy
+35.4% avg upside
29 analysts
$73.00
21.64% Upside
 -10.2% ·
LQDA
Liquidia Technologies
 Oct 17, 2025 BUY Strong Buy
+0.6% avg upside
15 analysts
$31.00
31.29% Downside
 +52.8% ·
TECX
Tectonic Therapeutic
 Oct 17, 2025 BUY Strong Buy
+176.4% avg upside
24 analysts
$101.00
410.55% Upside
 +19.6% ·
STRO
Sutro Biopharma
 Aug 12, 2025 HOLD Strong Buy
+357.6% avg upside
22 analysts
$30.00
229.62% Upside
 +173.1% ·
CABA
Cabaletta Bio
 Aug 08, 2025 HOLD Strong Buy
+832.2% avg upside
16 analysts
$2.00
32.42% Upside
 +105.2% ·
ZYME
Zymeworks
 Aug 07, 2025 HOLD Strong Buy
+18.3% avg upside
26 analysts
$14.00
50.98% Downside
 +93.6% ·
ZNTL
Zentalis Pharmaceuticals
 Aug 06, 2025 HOLD Buy
+585.1% avg upside
20 analysts
$5.00
155.09% Upside
 +262.3% ·
SMG
Scotts Miracle-Gro Company
 Dec 06, 2021 BUY Strong Buy
+29.3% avg upside
11 analysts
$180.00
189.16% Upside
 -60.7% ·
TSE:WEED
Canopy Growth
 Dec 06, 2021 SELL Hold
+1831.4% avg upside
23 analysts
$11.18
1102.20% Upside
 · ·
EQ
Equillium
 Jun 13, 2021 BUY Strong Buy
+585.2% avg upside
16 analysts
$12.00
775.95% Upside
 -66.3% ·
HRTX
Heron Therapeutics
 May 13, 2021 BUY Strong Buy
+10208.0% avg upside
21 analysts
$27.00
9622.73% Upside
 · ·
URGN
Urogen Pharma
 May 13, 2021 BUY Strong Buy
+42.4% avg upside
16 analysts
$30.00
8.24% Downside
 -61.3% ·
RNAC
Cartesian Therapeutics
 May 13, 2021 HOLD Strong Buy
+378.5% avg upside
19 analysts
$3.00
53.71% Downside
 -75.1% ·
LKFT
Lakefront Biotherapeutics
 May 09, 2021 HOLD Buy
+217.3% avg upside
25 analysts
$97.00
200.52% Upside
 -23.1% ·
MDGL
Madrigal Pharmaceuticals
 May 06, 2021 HOLD Strong Buy
+20.2% avg upside
34 analysts
$130.00
69.84% Downside
 -49.0% ·
DBVT
DBV Technologies SA - American
 May 03, 2021 HOLD Strong Buy
+143.7% avg upside
15 analysts
$6.00
36.85% Downside
 -79.3% ·
AMRN
Amarin
 Apr 29, 2021 HOLD Hold
-28.6% avg upside
18 analysts
$6.00
50.39% Downside
 -48.7% ·
VKTX
Viking Therapeutics
 Apr 28, 2021 BUY Strong Buy
+172.0% avg upside
31 analysts
$13.00
52.27% Downside
 -62.0% ·
FR:IVA
Inventiva
 Mar 05, 2021 BUY Strong Buy
+463.8% avg upside
6 analysts
$16.96
433.13% Upside
 -12.4% ·
IVA
Inventiva
 Mar 05, 2021 BUY Strong Buy
+350.3% avg upside
17 analysts
$19.00
420.52% Upside
 -20.1% ·
GB:0QW0
arGEN X
 Mar 04, 2021 HOLD Strong Buy
-23.5% avg upside
25 analysts
$297.17
63.13% Downside
 -3.7% ·
NL:LKFT
Lakefront Biotherapeutics NV
 Feb 19, 2021 HOLD Sell
+75.8% avg upside
17 analysts
$96.00
231.96% Upside
 -16.7% ·
FR:GNFT
Genfit
 Sep 30, 2020 BUY Strong Buy
+176.2% avg upside
5 analysts
$11.00
1.25% Upside
 -14.7% ·
VNDA
Vanda
 Jul 10, 2020 HOLD Strong Buy
+411.2% avg upside
13 analysts
 — +78.6% ·
PCRX
Pacira Pharmaceuticals
 Jul 10, 2020 HOLD Buy
+11.8% avg upside
23 analysts
 — -1.5% ·
ZVRA
Zevra Therapeutics
 Apr 02, 2018 BUY Strong Buy
+113.0% avg upside
15 analysts
$13.00
26.41% Upside
 -72.9% ·
TRVN
Trevena
 Mar 22, 2018 BUY Buy
+128278.4% avg upside
11 analysts
 — · ·
PRGO
Perrigo Company
 Mar 05, 2018 BUY Buy
+333.3% avg upside
20 analysts
$98.00
521.12% Upside
 -39.2% ·
TPST
Tempest Therapeutics
 Nov 09, 2017 HOLD Buy
+4215.3% avg upside
18 analysts
 — · ·
VTRS
Viatris
 Oct 03, 2017 HOLD Buy
+25.5% avg upside
22 analysts
 — +12.5% ·
🔒 59 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Derek Archila — Frequently Asked Questions
How accurate are Derek Archila's stock ratings?
Based on the calls 13Foresight could measure, about 48% of Derek's ratings were profitable over a one-year hold, with an average return of +3.3% per rating, or +22.9% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Derek ranked on 13Foresight?
Derek Archila is currently ranked #2068 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Derek cover?
Derek most recently has ratings on ANNX, BBIO, XFOR, INCY, ALNY, KYMR, XNCR, ARGX, IRON, PFE, IMVT, ONC and 52 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.